Breakthrough Research. New Perspectives. Actionable Insights.
Designed for business and science leaders like you
Harvard Medical School (HMS) continues to monitor the ongoing COVID-19 health situation. Following guidance from Harvard University leadership as well as the U.S. Centers for Disease Control and the Massachusetts Department of Public of Health, the format and dates for at least some HMS Executive Education programs will change.
Please refer to each individual program page for the latest updates.
From functional genomics and drug discovery, to health care policy and benefits, oncology and the microbiome, HMS’s executive-level open enrollment programs deliver new insights that position business and science leaders to unlock opportunities in a dynamic and rapidly changing health care landscape.
Programs are taught by HMS faculty, faculty from other Schools at Harvard University and industry-leading practitioners.
Program Offerings
-
Driving Health Care Strategy: Insights from Inside the Ecosystem
Led by Stanley Y. Shaw, MD, PhDSeptember 16-18, 2020Previously only available to companies on a customized basis, this flagship offering provides a comprehensive view into the converging forces transforming health care and inside access to the front lines of medicine. The program is designed for professionals across a wide range of health care related industries including biopharma, technology, financial and other professional services, medical device and provider organizations.
Learn more on our program page here.
-
Leading Digital Transformation in Health Care
Led by John Halamka, MD, MSMay 14 - 15, 2020This program is designed to provide you with the knowledge, tools and strategies to design and implement technology-enabled change initiatives in health care. Topics will include the Internet of Things, machine learning, telemedicine, change management, population management, wearables and behavioral health and policy implications.
Learn more on our program page here.
-
Accelerating Biotech and Pharmaceutical R&D through Genomics
Led by Sekar Kathiresan, MDJune 2-3, 2020Delve into the use of genomics in common and rare diseases, and throughout the drug discovery, development, regulatory and post-regulatory phases. This program informs decisions about R&D priorities and directions, evaluation of internal and external opportunities and strategic planning.
Learn more on our program page here.